Stay updated with breaking news from Nasdaq Drrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Analysts expect DURECT Co. (NASDAQ:DRRX – Get Rating) to post ($0.04) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for DURECT’s earnings. DURECT also reported earnings per share of ($0.04) during the same quarter last year. The company is scheduled to announce its next quarterly […]
StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX – Get Rating) in a note issued to investors on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock. Separately, Zacks Investment Research lowered shares of DURECT from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. […]
DURECT Co. (NASDAQ:DRRX – Get Rating) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totalling 14,590,000 shares, a growth of 42.3% from the April 15th total of 10,250,000 shares. Based on an average trading volume of 751,700 shares, the days-to-cover ratio is presently […]
Several brokerages have updated their recommendations and price targets on shares of DURECT (NASDAQ: DRRX) in the last few weeks: 5/7/2022 – DURECT is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 5/5/2022 – DURECT was downgraded by analysts at Zacks Investment Research from a “hold” rating to a […]
Wall Street analysts forecast that DURECT Co. (NASDAQ:DRRX – Get Rating) will post $2.43 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for DURECT’s earnings. The lowest sales estimate is $2.00 million and the highest is $2.85 million. DURECT posted sales of $2.21 million during the same […]